ECOR · electroCore, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Notwithstanding the expected cash flow from operations and expected access to capital from existing and/or future debt and equity sources, the Company’s currently forecasted cash is less than the requirements to fund its operating expenses and capital expenditure requirements, as currently planned, for at least the next 12 months from the date the accompanying condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 |
electroCore Announces Second Quarter 2026 Financial Results
Second quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% |
| 2026-08-03 |
electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences: Needham 11th Annual Virtual MedTech and Diagnostics Conference, |
| 2026-07-30 |
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, |
| 2026-07-16 |
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the |
| 2026-06-17 |
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. |
| 2026-06-09 |
Frontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
ROCKAWAY, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the review article, "Without getting under your skin: non-invasive stimulation activates the vagus nerve," has been accepted for |
| 2026-06-02 |
electroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
ROCKAWAY, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be presenting at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub being held at the Bellagio Resort & Casino in Las |
| 2026-05-13 |
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, “Transcutaneous Electrical Nerve Stimulation and Pain With |
| 2026-05-09 |
electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, |
| 2026-05-06 |
electroCore Announces First Quarter 2026 Financial Results
First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million Company to host a conference call and webcast today, May 6, 2026, at 4:30 pm EDT |
| 2026-04-30 |
electroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge
ROCKAWAY, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that TAC-STIM™, its non-invasive vagus nerve stimulation (nVNS) product for human performance, has been named a national semifinalist |
| 2026-04-29 |
electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first quarter ended March 31, 2026, after the close of the market on Wednesday, May 6, |
| 2026-04-28 |
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers Investor Summit at the historic Bank of New York. |
| 2026-04-23 |
electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
ROCKAWAY, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced its participation in Hacking the Vagus Nerve, a documentary from the Healing Journeys series produced by The Root Cause Project and |